Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) Pressured by Selling

Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) is a one man show now, moving as Dr. Philip Frost demands. Currently BZNE stands at 54 cents, after three days of active selling. Wednesday saw $3.10 millions’ worth of shares shed, yet the price moved only slightly, by about 4%. Dr. Frost, CEO of Opko Health, Inc., and other internal investors hold warrants at 40 cents, and have all incentives not to sell stocks below that price.

Despite the low volumes in the past months, BZNE is seen as a promising company that could shoot up, based on the earnings of its technology for the delivery of active ingredients. Its QuSomes patent is being tested and prepared to serve in the creation of cancer treatments. Currently, the technology is used in cosmetics, licensed to other leading brands.

But for all its worth and promise, BZNE is tightly controlled, and is protected from promoters. The company has just 69 million shares outstanding, a market cap of around $37 million. Total insider shares held are reported to be 5.6 million.

With so many pharmaceutical stocks active right now, BZNE is attracting its share of attention, though it’s a wait-and-see game. There are prognoses that the time for BZNE may come, and it would shoot up to three times its price. But the ticker is guarded by too many pressures, so it is best to decide on the time horizon before committing to buy BZNE.

A long-term mover that attracts great loyalty and interest is the Advanced Cell Technology, Inc. (OTCMKTS:ACTC). The stock is now making a run upward, though within a limited range, between 5 and 7 cents.

And if you are looking for another solid company that is having its moment, look no further than Where Food Comes From, Inc. (OTCBB:WFCF), the household name for food certification services. WFCF traded actively, nearly doubling in September, going toward $2.10.

While BZNE seems to have a lot going on, we can’t know when it would break its silence. More news would change the picture, but until then do not rely on a guaranteed breakthrough. BZNE opened up on Thursday, but the end of the day should come to show where the ticker is headed, at least in the short-term.